Agent(s) | Target(s) | Effect(s) | Stage of development | Study number(s) |
---|---|---|---|---|
CB-1158 | Arginase 1 | Inhibits Arginase | Phase I/II | NCT02903914 |
Phase I | NCT03910530 | |||
Phase I/II | NCT03314935 | |||
Phase I/II | NCT03837509 | |||
Phase I/II | NCT03361228 | |||
2DG | Hexokinase | Inhibits glycolysis | Phase I(completed) | NCT00096707 |
3PO/PFK15 | PFKFB3 | Inhibits glycolysis | Preclinical(97-100) | Â |
Shikonin | PKM2 | Inhibits PKM2 | Preclinical(103-105) | Â |
DCA | PDK1 | Inhibits PDK | Phase II | NCT01386632 |
Phase I | NCT01111097 | |||
Phase II | NCT00540176 | |||
GKT137831 | NOX4 | Inhibits NOX4 | Phase II | NCT03226067 |
CB839 | GLS | Inhibits glutamine metabolism | Phase I/II | NCT03875313 |
Phase I/II | NCT02861300 | |||
Phase II | NCT03163667 | |||
Others | Others | |||
PX-478 | HIF-1α | Inhibits HIF-1α | Phase I | NCT00522652 |
EZN-2968 | HIF-1α | Inhibits HIF-1α | Phase I | NCT01120288 |
Temsirolimus/ Everolimus | mTOR | Inhibits mTOR | FDA approved | >100 |
Ridaforolimus | mTOR | Inhibits mTOR | Phase II | NCT00086125 |
Phase II | NCT00122343 | |||
Phase II | NCT00739830 | |||
Phase III | NCT00538239 | |||
Phase II | NCT00093080 | |||
 | (Completed) | |||
Perifosine | AKT | Inhibits AKT | Phase I | NCT02238496 |